- Home
- SENEA vs PSNL Comparison
SENEA vs PSNL Comparison
Compare SENEA & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEA | PSNL |
|---|---|---|
| Founded | 1949 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 817.6M | 729.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SENEA | PSNL |
|---|---|---|
| Price | $123.99 | $8.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 45.0K | ★ 1.4M |
| Earning Date | 02-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.79 | N/A |
| EPS | ★ 8.61 | N/A |
| Revenue | ★ $1,606,175,000.00 | $69,103,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.41 |
| P/E Ratio | $13.21 | ★ N/A |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $77.08 | $2.83 |
| 52 Week High | $134.14 | $11.50 |
Technical Indicators
Market Signals| Indicator | SENEA | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 47.43 |
| Support Level | $116.82 | $7.95 |
| Resistance Level | $128.64 | $9.04 |
| Average True Range (ATR) | 5.35 | 0.74 |
| MACD | 0.60 | -0.10 |
| Stochastic Oscillator | 49.21 | 40.25 |
Price Performance
Historical ComparisonAbout SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.